Updates in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

New Orleans, LA US
December 13, 2022

This activity will give a brief review of Diffuse Large B-cell as a disease state and dive into the treatment algorithm to understand the clinical gap addressed by the new therapies. Audience members will then gain knowledge in the approval literature of related CAR T-cell therapies and antibody drug conjugates as well as pharmacologic pearls necessary for proper monitoring and implementation in our practice.

Target Audience

This activity intended for pharmacists and pharmacy technicians. 

Learning Objectives

At the conclusion of this activity, pharmacists should be able to: 

  • Review diffuse large B-cell lymphoma’s (DLBCL) epidemiology, treatment, and prognosis
  • Discuss pertinent literature regarding use of antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies for the treatment of Relapsed/Refractory (R/R) DLBCL
  • Identify the current place in therapy of ADCs and CAR T-cell therapy in the treatment of relapsed/refractory DLBCL
  • Recognize appropriate techniques for adverse effect management regarding use of previously described drugs


At the conclusion of this activity, pharmacy technicians should be able to: 

  • Recognize brand and generic names of new pharmacological agents used in treatment of R/R DLBCL
  • Review specific storage and handling information regarding compounded agents in R/R DLBCL

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE – Attendance
Course opens: 
Course expires: 
Event starts: 
12/13/2022 - 12:00pm CST
Event ends: 
12/13/2022 - 1:00pm CST
Ochsner Medical Center
1514 Jefferson Hwy
New Orleans, LA 70121
United States


Lauren Eichinger, PharmD
PGY2 Oncology Pharmacy Resident
Tom & Gayle Benson Cancer Center
Ochsner Medical Center

Planning committee

Breanne Peyton-Thomas, PharmD, BCOP
Clinical Hematology/Oncology Pharmacist
Ochsner Medical Center

Identification, Mitigation, and Disclosure of Relevant Financial Relationships

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

Disclosure of Relevant Financial Relationships:

Relevant Financial Relationships 

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

Breanne Peyton-Thomas, PharmD, BCOP, planner for this educational activity, has advisory and consultant from Janssen Pharmaceuticals and Oncology Reimbursement Management, Inc.

All relevant financial relationships listed for these individual(s) have been mitigated.

All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Statement of content validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

FDA off-label/unapproved usage

Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.

Off-label/unapproved drug uses or products are mentioned within this activity.

Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.

Joint Accreditation Statement:

In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement(s):


Vizient, Inc. designates this activity for a maximum of 1.0 ACPE credit hours.

Universal Activity Number: JA0006103-9999-22-185-L01-P

Universal Activity Number: JA0006103-9999-22-185-L01-T


Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation indicating the maximum credits available. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE – Attendance
Please login or register to take this course.